FINWIRES · TerminalLIVE
FINWIRES

HKG:2575

5 stories mentioning HKG:2575

Every FINWIRES story that references HKG:2575, newest first.

Asia

Xuanzhu Biopharm Cancer Drug Found to Benefit Patients in Study

Sihuan Pharmaceutical Holdings Group (HKG:0460) said a drug developed by its non wholly-owned subsidiary Xuanzhu Biopharmaceutical (HKG:2575) was found to benefit patients with lung cancer in a late-stage study, according to a Hong Kong bourse filing Monday.Results from the phase 3 clinical trial showed that dirozalkib demonstrated "statistically and clinically significant efficacy advantages" in the first-line treatment of ALK-positive advanced non-small cell lung cancer.In the modified intention-to-treat population, the drug was found to have achieved a median progression-free survival of 31.3 months compared with 12.9 months in the control group.The drug's objective response rate stood at 88.5% with a median duration of response of 32.10 months and a disease control rate of 95.4%.The firm presented the trial results at the 2026 American Association for Cancer Research annual meeting.

HKG:0460HKG:2575
Asia

Xuanzhu Biopharma Wins HKEX Nod for Hong Kong Share Full Circulation

Xuanzhu Biopharmaceutical (HKG:2575) said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Friday bourse filing.The approval covers the conversion of about 357.2 million unlisted shares into Hong Kong-listed shares.The converted shares represent about 69% of the company's total share capital.

HKG:2575
Asia

Hong Kong Stocks Edge Higher as U.S.-Iran Talks Remain in Focus; Xuanzhu Biopharm Advances

Hong Kong equities gained on Wednesday as expectations of renewed U.S.-Iran dialogue eased geopolitical concerns.The Hang Seng Index gained 75.00 points to end fractionally higher at 25,947.32, while the Hang Seng China Enterprises Index added 46.65 points, or 0.5%, to 8,718.26.U.S. President Donald Trump said talks with Iran could resume within days after weekend negotiations broke down in Islamabad, Reuters reported.Officials in Pakistan and Iran also indicated that discussions could restart.Despite the optimism, the U.S. said its military had effectively halted all maritime trade to and from Iran, maintaining pressure on Tehran.Oil prices extended declines for a second straight session as prospects of renewed talks reduced concerns over supply disruptions.Still, refiners continued to seek alternative crude supplies, driving up premiums for barrels from regions such as the U.S. Gulf Coast and the North Sea.In corporate news, Xuanzhu Biopharmaceutical (HKG:2575) closed over 10% higher after receiving approval in China to initiate a phase 3 trial for its Helicobacter pylori drug.

Hang SengHKG:2575
Asia

Xuanzhu Biopharm Gets China Approval to Start Phase 3 Helicobacter Pylori Drug Trial

Xuanzhu Biopharmaceutical (HKG:2575) received approval in China to initiate a phase 3 clinical trial of anaprazole sodium, according to a Wednesday Hong Kong bourse filing by parent Sihuan Pharmaceutical (HKG:0460).The trial will evaluate the drug as part of a bismuth-containing quadruple therapy for the eradication of Helicobacter pylori infection, and plans to enroll 556 adult patients.

HKG:0460HKG:2575
Asia

Xuanzhu Biopharmaceutical Receives Chinese Regulatory Nod to Begin Trials of An Jiu Wei

Xuanzhu Biopharmaceutical (HKG:2575) said it received Chinese regulatory approval to begin phase 3 clinical trials of its drug An Jiu Wei to treat Helicobacter pylori, according to a Hong Kong bourse filing Wednesday.The firm plans to enroll 556 adult subjects in the study.An Jiu Wei is already approved in China as a treatment of duodenal ulcer.

HKG:2575